These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 22246948)
1. Can we predict stroke in atrial fibrillation? Lip GY Clin Cardiol; 2012 Jan; 35 Suppl 1(Suppl 1):21-7. PubMed ID: 22246948 [TBL] [Abstract][Full Text] [Related]
2. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study. Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375 [TBL] [Abstract][Full Text] [Related]
3. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Mason PK; Lake DE; DiMarco JP; Ferguson JD; Mangrum JM; Bilchick K; Moorman LP; Moorman JR Am J Med; 2012 Jun; 125(6):603.e1-6. PubMed ID: 22502952 [TBL] [Abstract][Full Text] [Related]
4. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Lip GY Am J Med; 2011 Feb; 124(2):111-4. PubMed ID: 20887966 [TBL] [Abstract][Full Text] [Related]
5. Comparison between CHADS2 and CHA2 DS2 -VASc score in a stroke cohort with atrial fibrillation. Giralt-Steinhauer E; Cuadrado-Godia E; Ois A; Jiménez-Conde J; Rodríguez-Campello Á; Soriano C; Roquer J Eur J Neurol; 2013 Apr; 20(4):623-8. PubMed ID: 22834861 [TBL] [Abstract][Full Text] [Related]
6. [Anticoagulation in atrial fibrillation. Strategies in special situations]. Volkmann H; Walter M; Walter C; Vetter S Clin Res Cardiol Suppl; 2011 May; 6():58-65. PubMed ID: 22528179 [TBL] [Abstract][Full Text] [Related]
7. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study. Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge. Dupree L; DeLosSantos M; Smotherman C J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):502-508. PubMed ID: 29806486 [TBL] [Abstract][Full Text] [Related]
9. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Lip GY; Laroche C; Popescu MI; Rasmussen LH; Vitali-Serdoz L; Dan GA; Kalarus Z; Crijns HJ; Oliveira MM; Tavazzi L; Maggioni AP; Boriani G Europace; 2015 Dec; 17(12):1777-86. PubMed ID: 26321406 [TBL] [Abstract][Full Text] [Related]
10. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744 [TBL] [Abstract][Full Text] [Related]
11. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231 [TBL] [Abstract][Full Text] [Related]
12. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Coppens M; Eikelboom JW; Hart RG; Yusuf S; Lip GY; Dorian P; Shestakovska O; Connolly SJ Eur Heart J; 2013 Jan; 34(3):170-6. PubMed ID: 23018151 [TBL] [Abstract][Full Text] [Related]
13. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study. Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Prostran MS; Lip GY Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):319-26. PubMed ID: 22319004 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Friberg L; Rosenqvist M; Lip GY Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443 [TBL] [Abstract][Full Text] [Related]
15. Advances in stroke prevention in atrial fibrillation: enhanced risk stratification combined with the newer oral anticoagulants. Verheugt FW Clin Cardiol; 2013 Jun; 36(6):312-22. PubMed ID: 23568790 [TBL] [Abstract][Full Text] [Related]
16. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Lip GY; Connolly S; Yusuf S; Shestakovska O; Flaker G; Hart R; Lanas F; Xavier D; Eikelboom J; Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):31-8. PubMed ID: 23390125 [TBL] [Abstract][Full Text] [Related]
17. Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice. Romero-Ortuno R; O'Shea D Age Ageing; 2012 Mar; 41(2):250-4. PubMed ID: 22156597 [TBL] [Abstract][Full Text] [Related]
18. CHA(2)DS(2)-VASc versus CHADS(2) for stroke risk assessment in low-risk patients with atrial fibrillation: a pilot study from a single center of the NCDR-PINNACLE registry. Piyaskulkaew C; Singh T; Szpunar S; Saravolatz L; Rosman H J Thromb Thrombolysis; 2014 May; 37(4):400-3. PubMed ID: 23943340 [TBL] [Abstract][Full Text] [Related]
19. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. Olesen JB; Lip GY; Hansen ML; Hansen PR; Tolstrup JS; Lindhardsen J; Selmer C; Ahlehoff O; Olsen AM; Gislason GH; Torp-Pedersen C BMJ; 2011 Jan; 342():d124. PubMed ID: 21282258 [TBL] [Abstract][Full Text] [Related]
20. Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Marín F; Lip GYH Thromb Haemost; 2021 Aug; 121(8):1107-1114. PubMed ID: 33296920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]